NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Adverum Biotechnologies Inc (NASDAQ: ADVM)
ADVM Technical Analysis
3
As on 9th Jun 2023 ADVM STOCK Price closed @ 1.56 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.23 & Buy for SHORT-TERM with Stoploss of 1.56 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ADVMSTOCK Price
Open | 1.50 | Change | Price | % |
High | 1.62 | 1 Day | 0.09 | 6.12 |
Low | 1.47 | 1 Week | 0.33 | 26.83 |
Close | 1.56 | 1 Month | 0.74 | 90.24 |
Volume | 1140100 | 1 Year | -0.31 | -16.58 |
52 Week High 1.95 | 52 Week Low 0.54 |
NASDAQ USA Most Active Stocks
TSLA | 244.40 | 4.06% |
TTOO | 0.07 | -12.50% |
SOFI | 8.18 | 0.74% |
FFIE | 0.33 | 6.45% |
PONO | 1.72 | 2.38% |
AMD | 124.92 | 3.20% |
IDEX | 0.06 | 0.00% |
NKLA | 0.70 | 14.75% |
AMZN | 123.43 | -0.66% |
AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
ADVM Daily Charts |
ADVM Intraday Charts |
Whats New @ Bazaartrend |
ADVM Free Analysis |
|
ADVM Important Levels Intraday
RESISTANCE | 1.85 |
RESISTANCE | 1.76 |
RESISTANCE | 1.70 |
RESISTANCE | 1.64 |
SUPPORT | 1.48 |
SUPPORT | 1.42 |
SUPPORT | 1.36 |
SUPPORT | 1.27 |
ADVM Forecast May 2024
4th UP Forecast | 2.33 |
3rd UP Forecast | 2.08 |
2nd UP Forecast | 1.93 |
1st UP Forecast | 1.78 |
1st DOWN Forecast | 1.34 |
2nd DOWN Forecast | 1.19 |
3rd DOWN Forecast | 1.04 |
4th DOWN Forecast | 0.79 |
ADVM Weekly Forecast
4th UP Forecast | 2.14 |
3rd UP Forecast | 1.95 |
2nd UP Forecast | 1.84 |
1st UP Forecast | 1.72 |
1st DOWN Forecast | 1.40 |
2nd DOWN Forecast | 1.28 |
3rd DOWN Forecast | 1.17 |
4th DOWN Forecast | 0.98 |
ADVM Forecast2024
4th UP Forecast | 4.47 |
3rd UP Forecast | 3.54 |
2nd UP Forecast | 2.96 |
1st UP Forecast | 2.38 |
1st DOWN Forecast | 0.74 |
2nd DOWN Forecast | 0.16 |
3rd DOWN Forecast | -0.42 |
4th DOWN Forecast | -1.35 |
Adverum Biotechnologies Inc ( NASDAQ USA Symbol : ADVM )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ADVM Other Details
Segment | EQ | |
Market Capital | 206064384.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
ADVM Address
ADVM Latest News
ADVM Business Profile
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Address: 800 Saginaw Drive, Redwood City, CA, United States, 94063
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service